IL-1, IL-18, and IL-33 families of cytokines

Immunological Reviews

Volumn 223, Issue 1, 2008, Pages 20-38

  Arend, William P ^a   Palmer, Gaby ^b,c   Gabay, Cem ^b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Cytokines; Inflammatory diseases; Interleukin 1; Interleukin 18; Interleukin 33

Indexed keywords

BINDING PROTEIN; BLEOMYCIN; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1F7; INTERLEUKIN 33; INTERLEUKIN 8; INTERLEUKIN 8 BINDING PROTEIN; PLACEBO; PRALNACASAN; PROTEIN; PROTEIN NALP 3; PROTEIN T1 ST2; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; URIC ACID;

ADAPTIVE IMMUNITY; ARTHRITIS; ATHEROSCLEROSIS; AUTOINFLAMMATORY DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG MECHANISM; ENTERITIS; GOUT; HUMAN; INFLAMMATORY DISEASE; INNATE IMMUNITY; LUNG FIBROSIS; MAST CELL; METABOLIC SYNDROME X; MOUSE; MULTIPLE SCLEROSIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STROKE; TH2 CELL;

ALTERNATIVE SPLICING; ANIMALS; CARRIER PROTEINS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOTHERAPY; INTERLEUKIN-1; INTERLEUKIN-18; INTERLEUKINS; MICE; MUTATION; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 47249089097     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00624.x     Document Type: Review

References (204)

1. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996 87 : 2095 2147.
2. Arend WP, Evans CH. Interleukin-1 receptor antagonist (IL-1Ra). In : Thomson AW, Lotze MT, eds. The Cytokine Handbook, 4th edn. London, UK : Elsevier, 2003 : 669 708.
3. Liew FY, Xu D, Brint EK, O'Neill LAJ. Negative regulation of toll-like receptor-mediated immune responses. Nature Rev Immunol 2005 5 : 446 458.
4. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005 26 : 447 454.
5. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of IL-1β. Mol Cell 2002 10 : 417 426.
6. Mariathasan S, Monack FM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007 7 : 31 40.
7. 7 receptor: a key player in IL-1 processing and release. J Immunol 2006 176 : 3877 3883.
8. Sutterwala FS, et al. Critical role of NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006 24 : 317 327.
9. Mariathasan S, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006 440 : 228 232.
10. Becker CE, O'Neill LAJ. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin Immunopathol 2007 29 : 239 248.
11. Qu Y, Farnchi L, Numez G, Dubyak GR. Nonclassical IL-1β secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol 2007 179 : 1913 1925.
12. 2 control lysosome-mediated IL-1β secretion: implications for inflammatory processes. Proc Natl Acad Sci USA 2004 101 : 9745 9750.
13. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A. Rapid secretion of interleukin-1β by microvesicle shedding. Immunity 2001 8 : 825 835.
14. Brough D, Rothwell NJ. Caspase-1-dependent processing of pro-interleukin-1β is cytosolic and precedes cell death. Am J Cell Sci 2007 120 : 772 781.
15. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005 17 : 586 589.
16. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004 117 : 561 574.
17. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Well syndrome. Nat Genet 2001 29 : 301 305.
18. Aganna E, et al. Associations of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002 46 : 2445 2452.
19. Agostini L, Martinon F., Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004 20 : 319 325.
20. Neven B, et al. Molecular basis of the spectral expression of NIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 2004 103 : 2809 2815.
21. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004 50 : 607 612.
22. Hoffman HM, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004 364 : 1779 1785.
23. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005 52 : 1283 1286.
24. Goldbach-Mansky R, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. New Engl J Med 2006 355 : 581 592.
25. Gattorno M, et al. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007 56 : 3138 3148.
26. Dinarello CA. Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1β secretion and disease activity. Arthritis Rheum 2007 56 : 2817 2822.
27. Matzinger P. The danger model: a renewed sense of self. Science 2002 296 : 301 305.
28. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006 126 : 659 662.
29. Martinon F. Detection of immune danger signals by NALP3. J Leukoc Biol 2008 83 : 1 5.
30. Pétrelli V, Dostert C, Muruve D, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007 19 : 1 8.
31. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003 425 : 516 521.
32. Martinon F, Pétrelli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006 440 : 237 241.
33. Chen C-J, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urea crystals. J Clin Invest 2006 116 : 2262 2271.
34. Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout. Arthritis Rheum 2007 56 : 3183 3188.
35. So A, De Smedt T, Rervaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Therapy 2007 9 : R28.
36. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993 54 : 167 227.
37. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998 16 : 27 55.
38. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002 13 : 323 340.
39. Horai R, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000 191 : 313 320.
40. Nakae S, Asano M, Horai R, Sakaguchi N, Iwakura Y. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J Immunol 2001 167 : 90 97.
41. Horai R, et al. TNF-α is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 2004 114 : 1603 1611.
42. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003 100 : 5986 5990.
43. Cho M-L, et al. STAT3 and NF-κB signal production is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 2006 176 : 5652 5661.
44. Abdollahi-Roodsaz S, et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008 118 : 205 216.
45. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005 201 : 1479 1486.
46. Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA. Rapid response to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005 52 : 1794 1803.
47. Allantz F, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007 204 : 2131 2144.
48. Gasse P, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007 117 : 3786 3799.
49. Ortiz LA, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007 104 : 11002 11007.
50. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurol Sci 2000 23 : 618 625.
51. Lucas S-M, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Brit J Pharmacol 2006 147 : S232 S240.
52. Emsley HCA, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2006 76 : 1366 1372.
53. Perrier S, Darakhshan F, Hajduch E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde. FEBS Lett 2006 580 : 6289 6294.
54. Larsen CM, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New Engl J Med 2007 356 : 1517 1526.
55. Haskill S, et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA 1991 88 : 3681 3685.
56. 7 receptor activation. J Immunol 2004 173 : 1202 1208.
57. Wilson HL, et al. P2X receptor characterization and IL-1/IL-1Ra release from human endothelial cells. Brit J Pharmacol 2007 151 : 96 108.
58. Watson JM, et al. The intracellular IL-1 receptor antagonist alters IL-1-inducible gene expression without blocking exogenous signaling by IL-1β. J Immunol 1995 155 : 4467 4475.
59. Banda NK, et al. Intracellular IL-1 receptor antagonist type I inhibits IL-1-induced cytokine production in keratinocytes through binding to the third component of the COP9 signalosome. J Immunol 2005 174 : 3608 3616.
60. Kanangat S, Postlethwaite AE, Higgins GC, Hasty KA. Novel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosis. J Invest Dermatol 2006 126 : 756 765.
61. Francis SE, et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999 99 : 961 866.
62. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000 20 : 2394 2400.
63. Nicklin MJH, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000 191 : 303 311.
64. Dunn E, Sims JE, Nicklin MJH, O'Neill LAJ. Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol 2001 22 : 533 536.
65. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007 149 : 217 225.
66. Blumberg H, et al. Opposing activities of two novel members of the IL-1 family regulate skin inflammation. J Exp Med 2007 204 : 2603 2614.
67. Okamura H, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995 378 : 88 91.
68. Gu Y, et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997 275 : 206 209.
69. Zepter K, et al. Induction of biologically active IL-1 beta-converting enzyme and mature IL-1 beta in human keratinocytes by inflammatory and immunologic stimuli. J Immunol 1997 159 : 6203 6208.
70. Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol 1999 162 : 1096 1100.
71. Gracie JA, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999 104 : 1393 1401.
72. Horwood NJ, et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 1998 101 : 595 603.
73. Thomassen E, Bird TA, Renshaw BR, Kennedy MK, Sims JE. Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J Interferon Cytokine Res 1998 18 : 1077 1088.
74. Yoshimoto T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998 161 : 3400 3407.
75. Nakamura S, et al. Expression and responsiveness of human interleukin-18 receptor (IL-18R) on hematopoietic cell lines. Leukemia 2000 14 : 1052 1059.
76. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002 195 : 245 257.
77. Moller B, et al. Expression of interleukin-18 receptor in fibroblast-like synoviocytes. Arthritis Res 2002 4 : 139 144.
78. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002 14 : 117 122.
79. Gutzmer R, Langer K, Mommert S, Wittmann M, Kapp A, Werfel T. Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J Immunol 2003 171 : 6363 6371.
80. Airoldi I, et al. Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes. Clin Cancer Res 2004 10 : 144 154.
81. Hoshino K, et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 1999 162 : 5041 5044.
82. Sareneva T, Julkunen I, Matikainen S. IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J Immunol 2000 165 : 1933 1938.
83. Smeltz RB, Chen J, Hu-Li J, Shevach EM. Regulation of interleukin (IL)-18 receptor alpha chain expression on CD4(+) T cells during T helper (Th)1/Th2 differentiation. Critical downregulatory role of IL-4. J Exp Med 2001 194 : 143 153.
84. Neumann D, Martin MU. Interleukin-12 upregulates the IL-18Rbeta chain in BALB/c thymocytes. J Interferon Cytokine Res 2001 21 : 635 642.
85. Nakahira M, et al. An absolute requirement for STAT4 and a role for IFN-gamma as an amplifying factor in IL-12 induction of the functional IL-18 receptor complex. J Immunol 2001 167 : 1306 1312.
86. Smeltz RB, Chen J, Ehrhardt R, Shevach EM. Role of IFN-gamma in Th1 differentiation: IFN-gamma regulates IL-18R alpha expression by preventing the negative effects of IL-4 and by inducing/maintaining IL-12 receptor beta 2 expression. J Immunol 2002 168 : 6165 6172.
87. Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 2002 169 : 3600 3605.
88. Strengell M, et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 2003 170 : 5464 5469.
89. Hoeve MA, de Boer T, Langenberg DM, Sanal O, Verreck FA, Ottenhoff TH. IL-12 receptor deficiency revisited: IL-23-mediated signaling is also impaired in human genetic IL-12 receptor beta1 deficiency. Eur J Immunol 2003 33 : 3393 3397.
90. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999 10 : 127 136.
91. Kim SH, et al. Identification of amino acid residues critical for biological activity in human interleukin-18. J Biol Chem 2002 277 : 10998 11003.
92. Kim SH, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA 2000 97 : 1190 1195.
93. Paulukat J, et al. Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol 2001 167 : 7038 7043.
94. Kawashima M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001 44 : 550 560.
95. Moller B, et al. Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis. Rheumatology (Oxford) 2001 40 : 302 309.
96. Bresnihan B, Roux-Lombard P, Murphy E, Kane D, FitzGerald O, Dayer JM. Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis 2002 61 : 726 729.
97. Ludwiczek O, et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol 2002 22 : 331 337.
98. Corbaz A, et al. IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J Immunol 2002 168 : 3608 3616.
99. Mazodier K, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005 106 : 3483 3489.
100. Bufler P, et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci USA 2002 99 : 13723 13728.
101. Gutcher I, Urich E, Wolter K, Prinz M, Becher B. Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol 2006 7 : 946 953.
102. Lewis EC, Dinarello CA. Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor. Proc Natl Acad Sci USA 2006 103 : 16852 16857.
103. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003 73 : 213 224.
104. Grobmyer SR, et al. Elevation of IL-18 in human sepsis. J Clin Immunol 2000 20 : 212 215.
105. Seki E, et al. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol 2001 166 : 2651 2657.
106. Bachmann M, et al. Interleukin-18 secretion and Th1-like cytokine responses in human peripheral blood mononuclear cells under the influence of the toll-like receptor-5 ligand flagellin. Cell Microbiol 2006 8 : 289 300.
107. Pedra JH, et al. ASC/PYCARD and caspase-1 regulate the IL-18/IFN-gamma axis during Anaplasma phagocytophilum infection. J Immunol 2007 179 : 4783 4791.
108. Puren AJ, Razeghi P, Fantuzzi G, Dinarello CA. Interleukin-18 enhances lipopolysaccharide-induced interferon-gamma production in human whole blood cultures. J Infect Dis 1998 178 : 1830 1834.
109. Leung BP, et al. A role for IL-18 in neutrophil activation. J Immunol 2001 167 : 2879 2886.
110. Hyodo Y, et al. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol 1999 162 : 1662 1668.
111. Takeda K, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998 8 : 383 390.
112. French AR, Holroyd EB, Yang L, Kim S, Yokoyama WM. IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. Cytokine 2006 35 : 229 234.
113. Faggioni R, et al. IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 2001 167 : 5913 5920.
114. Okamoto I, Kohno K, Tanimoto T, Ikegami H, Kurimoto M. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12. J Immunol 1999 162 : 3202 3211.
115. Komai-Koma M, et al. Chemoattraction of human T cells by IL-18. J Immunol 2003 170 : 1084 1090.
116. Robinson D, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997 7 : 571 581.
117. Magram J, et al. IL-12-deficient mice are defective but not devoid of type 1 cytokine responses. Ann NY Acad Sci 1996 795 : 60 70.
118. Hunter SE, Waldburger KE, Thibodeaux DK, Schaub RG, Goldman SJ, Leonard JP. Immunoregulation by interleukin-12 in MB49.1 tumor-bearing mice: cellular and cytokine-mediated effector mechanisms. Eur J Immunol 1997 27 : 3438 3446.
119. Yoshimoto T, Okamura H, Tagawa YI, Iwakura Y, Nakanishi K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci USA 1997 94 : 3948 3953.
120. Hoshino T, et al. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 2001 166 : 7014 7018.
121. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006 24 : 677 688.
122. Fassbender K, et al. Interferon-gamma-inducing factor (IL-18) and interferon-gamma in inflammatory CNS diseases. Neurology 1999 53 : 1104 1106.
123. Nicoletti F, et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology 2001 57 : 342 344.
124. van Boxel-Dezaire AH, et al. Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis. J Neuroimmunol 2001 120 : 152 160.
125. Ito A, et al. Transfer of severe experimental autoimmune encephalomyelitis by IL-12- and IL-18-potentiated T cells is estrogen sensitive. J Immunol 2003 170 : 4802 4809.
126. Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001 166 : 517 521.
127. Plater-Zyberk C, et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001 108 : 1825 1832.
128. Banda NK, et al. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol 2003 170 : 2100 2105.
129. Smeets RL, van de Loo FA, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 2003 10 : 1004 1011.
130. Shi FD, et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000 1 : 245 251.
131. Santos LL, et al. IL-18 is redundant in T-cell responses and in joint inflammation in antigen-induced arthritis. Immunol Cell Biol 2006 84 : 166 173.
132. Ludwiczek O, Kaser A, Novick D, Dinarello CA, Rubinstein M, Tilg H. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. Eur Cytokine Netw 2005 16 : 27 33.
133. Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D. Plasma interleukin-18 reflects severity of ulcerative colitis. World J Gastroenterol 2005 11 : 605 608.
134. Salvati VM, et al. Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut 2002 50 : 186 190.
135. Pizarro TT, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999 162 : 6829 6835.
136. te Velde AA, et al. Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur J Immunol 2003 33 : 143 151.
137. Ishikura T, et al. Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice. J Gastroenterol Hepatol 2003 18 : 960 969.
138. Lochner M, Forster I. Anti-interleukin-18 therapy in murine models of inflammatory bowel disease. Pathobiology 2002 70 : 164 169.
139. Siegmund B, Sennello JA, Lehr HA, Senaldi G, Dinarello CA, Fantuzzi G. Frontline: interferon regulatory factor-1 as a protective gene in intestinal inflammation: role of TCR gamma delta T cells and interleukin-18-binding protein. Eur J Immunol 2004 34 : 2356 2364.
140. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005 2005 : 273 279.
141. Companjen A, van der Wel L, van der Fits L, Laman J, Prens E. Elevated interleukin-18 protein expression in early active and progressive plaque-type psoriatic lesions. Eur Cytokine Netw 2004 15 : 210 216.
142. Flisiak I, Klepacki A, Chodynicka B. Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers 2006 11 : 194 200.
143. Naik SM, et al. Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Dermatol 1999 113 : 766 772.
144. Ariizumi K, Kitajima T, Bergstresser OR, Takashima A. Interleukin-1 beta converting enzyme in murine Langerhans cells and epidermal-derived dendritic cell lines. Eur J Immunol 1995 25 : 2137 2141.
145. Wang B, et al. Contribution of Langerhans cell-derived IL-18 to contact hypersensitivity. J Immunol 2002 168 : 3303 3308.
146. Kawase Y, et al. Exacerbated and prolonged allergic and non-allergic inflammatory cutaneous reaction in mice with targeted interleukin-18 expression in the skin. J Invest Dermatol 2003 121 : 502 509.
147. Netea MG, et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006 12 : 650 656.
148. Mallat Z, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001 104 : 1598 1603.
149. Mallat Z, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001 89 : E414 E415.
150. Chang CY, et al. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model. BMC Cancer 2007 7 : 87.
151. Marshall DJ, et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine 2006 24 : 244 253.
152. Tomura M, et al. A critical role for IL-18 in the proliferation and activation of NK1.1+CD3-cells. J Immunol 1998 160 : 4738 4746.
153. Cho D, et al. Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy. J Invest Dermatol 2000 114 : 928 934.
154. Park H, et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett 2001 79 : 215 219.
155. Ye ZB, Ma T, Li H, Jin XL, Xu HM. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 2007 13 : 1747 1751.
156. Kim J, et al. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun 2006 344 : 1284 1289.
157. Kim KE, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 2007 26 : 1468 1476.
158. Zhang B, et al. IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinases-9 (MMP-9) expression. Leuk Res 2004 28 : 91 95.
159. Carrascal MT, et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003 63 : 491 497.
160. Cho D, et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 2000 60 : 2703 2709.
161. Le Buanec H, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 2006 103 : 19442 19447.
162. Ku G, Faust T, Lauffer LL, Livingston DJ, Harding MW. Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 1996 8 : 377 386.
163. Stack JH, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 2005 175 : 2630 2634.
164. Pavelka K, Rasmussen MJ, Mikkelsen K. Clinical effects of palnacasan (PRAL), an orally-active interleukin-1 beta converting enzyme (ICE) inhibitor, in a 285 patient phase II trial in rheumatoid arthritis. Arthritis Rheum 2002 46 : LB02.
165. Listing J, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005 52 : 3403 3412.
166. Genovese MC, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004 50 : 1412 1419.
167. Nishimoto N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007 66 : 1162 1167.
168. Schmitz J, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005 23 : 479 490.
169. Baekkevold ES, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003 163 : 69 79.
170. Werman A, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA 2004 101 : 2434 2439.
171. Carriere V, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007 104 : 282 287.
172. Trajkovic V, Sweet MJ, Xu D. T1/ST2 - an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 2004 15 : 87 95.
173. Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998 161 : 4866 4874.
174. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. Embo J 1994 13 : 1176 1188.
175. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007 117 : 1538 1549.
176. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007 282 : 26369 26380.
177. Brunner M, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004 30 : 1468 1473.
178. Tominaga S, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Komatsu N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun 1999 264 : 14 18.
179. Tago K, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 2001 285 : 1377 1383.
180. Meisel C, et al. Regulation and function of T1/ST2 expression on CD4+T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol 2001 166 : 3143 3150.
181. Brint EK, et al. Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2. A role for Jun N-terminal kinase in IL-4 induction. J Biol Chem 2002 277 : 49205 49211.
182. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007 179 : 2551 2555.
183. Iikura M, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007 87 : 971 978.
184. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 2007 104 : 18660 18665.
185. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007 37 : 2779 2786.
186. Lohning M, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998 95 : 6930 6935.
187. Amatucci A, Novobrantseva T, Gilbride K, Brickelmaier M, Hochman P, Ibraghimov A. Recombinant ST2 boosts hepatic Th2 response in vivo. J Leukoc Biol 2007 82 : 124 132.
188. Coyle AJ, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999 190 : 895 902.
189. Walzl G, et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med 2001 193 : 785 792.
190. Hoshino K, et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med 1999 190 : 1541 1548.
191. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000 191 : 1069 1076.
192. Mangan NE, Dasvarma A, McKenzie AN, Fallon PG. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol 2007 37 : 1302 1312.
193. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007 179 : 2051 2054.
194. Ho LH, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcεRI signals. J Leukoc Biol 2007 82 : 1481 1490.
195. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007 40 : 216 225.
196. Brint EK, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004 5 : 373 379.
197. Sweet MJ, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001 166 : 6633 6639.
198. Yin H, et al. Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury. Biochem Biophys Res Commun 2006 351 : 940 946.
199. Fagundes CT, et al. ST2, an IL-1R family member, attenuates inflammation and lethality after intestinal ischemia and reperfusion. J Leukoc Biol 2007 81 : 492 499.
200. Fraser A, Moore M, Jongbloed S, Gracie A, McInnes IB. Elevated soluble ST2 and cytokine levels in synovial fluids of patients with inflammatory synovitis. Ann Rheum Dis 2006 65 : A10.
201. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002 297 : 1689 1692.
202. Nigrovic PA, et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci USA 2007 104 : 2325 2330.
203. Xu D, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998 187 : 787 794.
204. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004 173 : 145 150.